Multiple Dose Study of Safety and Pharmacokinetics of MEDI0618 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

December 12, 2022

Primary Completion Date

December 12, 2023

Study Completion Date

December 12, 2023

Conditions
Chronic Pain
Interventions
DRUG

MEDI0618

Four doses of 100 mg IV, 200 mg IV or 200 mg SC MEDI0618 administered once every two weeks.

DRUG

Placebo

Four doses of IV placebo or SC placebo administered once every two weeks.

Trial Locations (1)

10117

Research Site, Berlin

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY